A novel fully synthetic immunotherapy platform designed to enhance both T- and B-cell responses through targeted antigen delivery and built-in immune activation. The technology is intended to improve the performance, stability, and manufacturability of peptide- and protein-based vaccines and immunotherapies across infectious disease, oncology, and other immune-mediated indications. Available for evaluation, licensing, and co-development discussions with partners seeking differentiated next-generation immunotherapy solutions.
